Cite

HARVARD Citation

    Mozessohn, L. et al. (2021). Real-World Costs of Azacitidine Treatment in Patients With Higher-Risk Myelodysplastic Syndromes/Low Blast–Count Acute Myeloid Leukemia. JCO oncology practice. 17 (4), p. . [Online]. 
  
Back to record